AstraZeneca’s Breztri Achieves Primary Endpoints in KALOS and LOGOS Phase III Trials, Marking a Significant Advance in the Treatment of Uncontrolled Asthma AstraZeneca announced encouraging high-level results from its pivotal Phase III KALOS and LOGOS clinical trials evaluating Breztri Aerosphere…
Vaccine Study Shows Fewer Side Effects with PharmaJet Needle-Free Delivery PharmaJet®, a company committed to advancing the performance, safety, and effectiveness of injectable vaccines and therapies through innovative needle-free injection technology, has announced the publication of a significant new study…
AI-Driven HSS Study Identifies Risk Factors for Severe Pain After Knee Replacement At the 50th Annual Meeting of the American Society of Regional Anesthesia and Pain Medicine (ASRA), a groundbreaking study utilizing artificial intelligence (AI) to classify patient pain archetypes…
New SURPASS-3 Data Links Tirzepatide to Muscle Composition Changes in Type 2 Diabetes In an increasingly dynamic and rapidly evolving field of metabolic disease management, the nuanced effects of weight loss therapies on body composition are gaining heightened scientific and…
Predicta Biosciences Unveils First Molecular Diagnostic for Enhancing Multiple Myeloma Prognosis Predicta Biosciences, a precision oncology company, has officially launched its first Laboratory Developed Test (LDT), GenoPredicta, a cutting-edge diagnostic tool designed for use in both blood and bone marrow…
Pilatus Biosciences Unveils Preclinical Data on CD36 Antibody PLT012 for Liver Cancer Pilatus Biosciences, a biotechnology company dedicated to developing next-generation immunometabolic therapies for cancer, has announced the publication of a pivotal preclinical study in Cancer Discovery, a leading peer-reviewed…
Guardant Health Showcases Strong Shield Test Results Across 10 Cancer Types At the 2025 Annual Meeting of the American Association for Cancer Research (AACR), Guardant Health, Inc. , a leader in precision oncology, unveiled compelling new data from a study…
LEAP Boosts Digital Lab Transformation with Key Executive Appointment in Clinical Diagnostics LEAP Consulting Group, a renowned boutique digital consultancy specializing in guiding national clinical diagnostic laboratories through complex, multi-phase digital transformations, has announced a strategic executive appointment that marks…
Pfizer’s Sasanlimab Boosts Event-Free Survival in High-Risk NMIBC Pfizer Inc. (NYSE: PFE) announced today significant findings from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody, in combination with the standard of care (SOC) Bacillus Calmette-Guérin…
UGN-102 Trials Show No Impact on Function, Symptoms, or QoL in LG-IR-NMIBC Patients UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company focused on developing and commercializing innovative treatments for urothelial and specialty cancers, announced new data supporting its investigational intravesical…
CytoAgents Completes Cohort 1 Dose-Escalation in Phase 1B Clinical Trial for Cytokine Release Syndrome Research CytoAgents Inc., a clinical-stage biotechnology company at the forefront of developing therapies for immune-mediated disorders, has announced a significant milestone in its ongoing Phase 1b/2a…
Debiopharm and Oncodesign Services Partner to Advance Radiopharmaceuticals in Preclinical Research Debiopharm Research & Manufacturing S.A. (Debiopharm), a privately held, Swiss-based global biopharmaceutical company committed to advancing the treatment landscape for cancer and infectious diseases, has announced a strategic licensing…